Browse the corpus

Linaclotide is an FDA-approved medication indicated for adults suffering from irritable bowel syndrome with predominant constipation (IBS-C) and chronic idiopathic constipation (CIC). Linaclotide, administered daily, is a potent and highly selective agonist of guanylate cyclase-C (GC-C) receptors in the intestine, offering a novel therapeutic approach with a favorable safety profile. Beyond its FDA-approved indications, linaclotide shows promise in managing refractory lower GI manifestations in systemic sclerosis patients and alleviating constipation induced by various factors such as opioid use, diabetes mellitus, neurological conditions, and post-surgery complications. With IBS-C and CIC affecting approximately 20% of the general population, including the geriatric community, safe and effective long-term prescribed treatments are needed when over-the-counter therapies fail. This activity equips clinicians with the necessary knowledge and skills to identify appropriate candidates for linaclotide therapy, set realistic treatment goals, ensure proper administration and monitoring, and foster collaboration among interprofessional healthcare team members to enhance patient outcomes. This activity describes the indications, mechanism of action, contraindications, adverse event profile, and other key factors pertinent to interprofessional team members when prescribing linaclotide. Objectives: Identify the common indications for linaclotide therapy, including irritable bowel syndrome with constipation and chronic idiopathic constipation. Apply evidence-based guidelines into the decision-making process when considering linaclotide as a treatment option for irritable bowel syndrome with constipation or chronic idiopathic constipation. Screen patients for contraindications associated with linaclotide therapy, ensuring a safe and effective treatment that mitigates adverse events. Collaborate with interprofessional team members, including gastroenterologists and pharmacists, to optimize the management of patients under linaclotide therapy. Access free multiple choice questions on this topic.

Accidental ingestion of linaclotide in children, particularly aged under 2, may cause severe diarrhea and dehydration. Patients need counseling regarding keeping the linaclotide container out of reach of children and discarding the unused linaclotide appropriately.[29]

Irritable bowel syndrome with prominent constipation (IBS-C) and CIC are functional GI disorders connected with constipation. IBS-C and CIC together affect about 20% of the general population, including the geriatric population, impairing the overall quality of life. When patients do not respond adequately to over-the-counter therapies, they need safe and effective long-term prescribed treatment. Patients might be intolerant to the more well-established medicines. For adults, linaclotide is a novel remedy with a favorable safety profile.[3] After obtaining the patient's informed verbal consent, providers such as primary care clinicians, gastroenterologists, nurse practitioners, and physician assistants prescribe linaclotide and set realistic goals for treatment outcomes. Nurses administer the linaclotide via feeding tube in in-patient settings. At discharge, they have opportunities to counsel the patients regarding the drug dosage, administration, treatment compliance, and circumstances when medical attention is necessary. Nurses can detect and report adverse effects to the consultants during follow-up visits. Pharmacists review the drug dosage, administration, and storage process in all healthcare settings and report concerns to the physicians. The patients are advised to read the FDA-approved labeling, take medicine regularly, at least 30 minutes before the day's first meal, and follow the prescriber's advice. A high-fiber diet, adequate fluid intake, and exercise have added benefits while on linaclotide. Patients should keep the medicine out of reach of children and dispose of the unused supply. Families should contact the poison control center immediately in cases of accidental ingestion by children. The collaboration and open communication among interprofessional healthcare team members will positively impact patient outcomes.